Global Hyaluronic Acid Market to Grow to $2.5 Billion by 2017
Growth Driven by Rising Global Rates of Osteoarthritis and Obesity, According to Millennium Research Group
TORONTO, Jan. 28, 2013 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, the patient pool for hyaluronic acid (HA) viscosupplementation will continue to expand globally, due to rising rates of osteoarthritis and obesity, leading to moderate growth in the global HA viscosupplementation market to nearly $2.5 billion by 2017.
The most significant treatment trend will continue to be the shift to premium-priced shorter treatment regimens, which offer more convenience for the patient and increase patient compliance with treatment. This trend will occur worldwide. While 5-injection treatments are still the leading choice for patients globally, the number is skewed by Japan, where more than 80 percent of such procedures were performed in 2011. One- and 3-injection treatments will continue to rise as a proportion of total treatments.
While HA viscosupplementation treatments are used primarily in the knee, there will be a shift toward using this treatment for other joints in the body, as physicians become more comfortable performing the procedure on non-knee areas. Manufacturers are investing in non-knee clinical trials to provide support for this shift.
"Despite the diverse competitive landscape for these products, two companies have captured over half the global market," said MRG Analyst Kristina Vidug. "While they both sell in all three major regions, Seikagu is strongest in Asia Pacific, while Sanofi dominates the United States market."
Companies that compete on price, introduce a product that is specific to a non-knee indication or release a single-injection product will be most successful in this market through 2017.
Millennium Research Group's Global Markets for Hyaluronic Acid Viscosupplementation 2013 report includes unit, average selling price and revenue information, along with market drivers and limiters and competitive landscape for HA viscosupplementation in the United States, Europe (France, Germany, Italy, Spain, and the United Kingdom), and the Asia Pacific and emerging markets (Australia, Brazil, China [Mainland China and Hong Kong], India, Japan, South Korea and Taiwan).
About Millennium Research Group
Millennium Research Group (www.MRG.net), a Decision Resources Group company (www.DecisionResourcesGroup.com), is the global authority on medical technology market intelligence and the leading provider of strategic information to the healthcare sector. The company provides specialized industry expertise through multiclient market research, ongoing Marketrack™ projects, customer loyalty tracking, facility-level procedure forecasting, and customized solutions.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact:
SOURCE Millennium Research Group
More by this Source
ARRA Funding Encourages EMR Purchases at the Expense of PACS, RIS and CVIS Systems
Dec 04, 2013, 08:00 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.